Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

Progress of Phase I Programme With Oral Iclaprim "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of

First Modules due Before Year-end 2007

REINACH, Switzerland, December 12 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today the enrolment and dosing of the first patients in the Phase II clinical study with intravenous iclaprim in the treatment of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) / healthcare-associated pneumonia (HCAP).

In addition, Arpida announced results of a Phase I study with oral iclaprim. The primary aim of the study was to assess the safety and tolerability of single ascending doses of an oral capsule formulation of iclaprim in healthy volunteers.

Moreover, Arpida today announced that the first modules of the New Drug Application (NDA) for intravenous iclaprim in its first indication, cSSSI, are ready and will be filed before year-end 2007. The filing of the NDA package is expected to be completed by the end of February 2008.

First patients enrolled in Phase II trial with intravenous iclaprim in HAP/VAP/HCAP

Patient recruitment has started and several additional clinical centres are expected to start recruiting within the next few weeks. The trial remains on track for completion in 2008.

HAP/VAP/HCAP as a potential second indication could substantially enhance iclaprim's prospects as a potent novel therapy against multi-drug resistant bacteria. In the area of pneumonia, the need for new drugs addressing MRSA-infections is particularly pressing.

The Phase II trial is designed as a multi-centre, randomised, double-blind, comparative study. The efficacy and safety of two different dosing regimens of iclaprim will be compared to the current standard of care vancomycin. More than 130 patients will be enrolled. Patients will be treated for 7-14 days and a Test-of-Cure (TOC) visit will be performed 7-14
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 Working in collaboration with the ... London , Richmond Pharmacology is the first centre ... study for an investigational RNAi therapeutic being developed for the ... nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/26/2015)... WARREN, N.J., March 26, 2015  Roka Bioscience, ... company focused on providing advanced testing solutions for ... financial results for the three months and full ... Quarter 2014 Financial Results:Revenue for the quarter ended ... $689,000 for the fourth quarter of 2013 and ...
(Date:3/26/2015)...  BioNano Genomics, Inc., the leader in genome mapping, ... chief commercial officer. Salyer has more than 20 years ... life sciences. At BioNano, Salyer will oversee the commercialization ... to assemble a comprehensive view of complex genomes to ... institutions located in the United States ...
(Date:3/26/2015)... 26, 2015 ReliantHeart, Inc., an innovative ... a supplier of precision transit-time flow measurement solutions, are ... improve the efficiency of the HeartAssist5® Left ... to experience greater mobility and peace of mind. ... flow board, will draw 1/6th of the power required ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... IDM Pharma (Nasdaq:,IDMI) today announced that Jeffrey W. ... Medical Officer and Senior Vice President,of Research and Development. ... report to President and CEO Timothy P. Walbert. ... experience to,IDM Pharma and will lead the regulatory and ...
... NanoLogix, Inc. (OTC:,NNLX) is pleased to announce that ... Director of Intellectual Property. In addition, we wish ... the rapid detection of,Anthrax utilizing the NanoLogix BioNanoChannel(TM) ... experience as an intellectual property,counsel in a wide ...
... Drug Royalty LP 2 (DRC) announced,today the ... worldwide,royalty interest in PEG-INTRON for $92.5M. DRC will ... certain royalty recognition levels be met.,PEG-INTRON (peginterferon alpha-2b), ... is marketed worldwide by Schering-Plough Corporation (SGP). ...
Cached Biology Technology:IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 4IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 5NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection 2NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection 3Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... wealth of fossils and impressions frozen in rocks that they ... ago ?when animals with shells and bones began to become ... years is scant and difficult to study. , Now, a ... Nanjing Institute of Geology and Paleontology in China has discovered ...
... propose a useful approach to feed the world's growing ... protein and oil and about half of its usual ... at UC Riverside, will present at a congressional seminar ... holds promise for efficiently feeding high-protein corn to people ...
... Grant has awarded Virginia Tech $119,000 to study whether ... both shucked and unshucked oysters. , The project, led ... Processing Laboratory, and Laura Douglas, lab manager, will identify ... laboratory is a facility of the Department of Food ...
Cached Biology News:Virginia Tech, Nanjing Institute researchers discover half-billion year-old fossils 2Virginia Tech, Nanjing Institute researchers discover half-billion year-old fossils 3UCR biochemist goes to Washington with high-protein corn 2Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied 2
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... consists of ten double-stranded RNAs, 10, 20, ... and 1,000 base pairs. The dsRNA Marker ... sizes of double-stranded RNAs. A twenty bp ... is adjusted to approximately 25 ng/µl in ...
... Mouse monoclonal antibody raised against ... Immunogen: HD ... a.a) partial recombinant protein with ... Accession Number: NM_002111 ...
... rocking platform, 120 V, is used for agitation ... liquid cultures, staining and destaining of gels and ... speed control (8-40 rpm) and can handle a ... rocker features two 29 x 21 cm platforms ...
Biology Products: